Étiquette : serotonine

Regulation of nausea and vomiting by cannabinoids, Linda A Parker et al., 2011

Regulation of nausea and vomiting by cannabinoids Linda A Parker, Erin M Rock and Cheryl L Limebeer British Journal of Pharmacology, 2011, 163, 1411-1422. Doi : 10.1111/j.1476-5381.2010.01176.x   Abstract Considerable evidence demonstrates that manipulation of the endocannabinoid system regulates nausea and vomiting in humans and other animals. The anti-emetic effect of cannabinoids has been shown across a wide variety of animals that are capable of vomiting in response to a toxic challenge. CB1 agonism suppresses vomiting, which is reversed by CB1 antagonism, and CB1 inverse agonism promotes vomiting. Recently, evidence from animal experiments suggests that cannabinoids may be especially useful in treating the more difficult to control [...]

Lire la suite

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, Keith A. Sharkey et al., 2014

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Keith A. Sharkey, Nissar A. Darmani, and Linda A. Parker European Journal of Pharmacology, 2014 January 5; 722. doi : 10.1016/j.ejphar.2013.09.068.   Abstract Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances. However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently observed as side-effects of a variety of medications, notably those used to treat cancer. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes.This has [...]

Lire la suite

Translational evidence for ayahuasca as an antidepressant : what’s next ?

Translational evidence for ayahuasca as an antidepressant : what’s next ? Rafael Guimaraes dos SANTOS, José Carlos BOUSO British Journal of Psychiatry, 2019, 41, (4), 275-276. Doi : 10.1590/1516-4446-2019-4104   Depression is among the most important contributors to global disability and suicidal deaths. Available antidepressants are usually selective inhibitors of serotonin and norepinephrine uptake, which need weeks of daily intake before therapeutic effects appear, have limited efficacy for many patients, and induce significant adverse reactions after prolonged use. Therefore, recent research has focused on finding new antidepressant compounds that are fast-acting, more effective, and less toxic. The article recently published by da Silva et al. in the [...]

Lire la suite

d-Lysergic acid diethylamide has major potential as a cognitive enhancer, Felipe Augusto Cini et al., 2019

d-Lysergic acid diethylamide has major potential as a cognitive enhancer Felipe Augusto Cini, Isis Ornelas, Encarni Marcos, Livia Goto-Silva, Juliana Nascimento, Sergio Ruschi, José Salerno, Karina Karmirian, Marcelo Costa, Eduardo Sequerra, Dráulio de Araújo, Luis Fernando Tófoli, César Rennó-Costa, Daniel Martins-de-Souza, Amanda Feilding, Stevens Rehen, Sidarta Ribeiro BioRxiv, 6 december 2019. Doi : 10.1101/866814   Abstract Psychedelic agonists of serotonin receptors induce neural plasticity and synaptogenesis, but their potential to enhance learning remains uncharted. Here we show that a single dose of d-LSD, a potent serotonergic agonist, increased novel object preference in young and adult rats several days after treatment. d- LSD alone did not increase preference [...]

Lire la suite

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers, Rainer Kraehenmann et al., 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010   Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]

Lire la suite

LSD enhances suggestibility in healthy volunteers, R. L. Carhart-Harris et al., 2014

LSD enhances suggestibility in healthy volunteers R. L. Carhart-Harris, M. Kaelen, M. G. Whalley, M. Bolstridge, A. Feilding, D. J. Nutt Psychopharmacology, 2014 DOI 10.1007/s00213-014-3714-z   Abstract Rationale : Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. Objectives : The present study sought to test the effect of LSD on suggestibility in a modern research study. Methods : Ten healthy volunteers were administered with intravenous (i.v.) LSD (40–80 μg) in a within-subject placebocontrolled design. Suggestibility and cued mental imagery were assessed using the Creative [...]

Lire la suite

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity, Rainer Kraehenmann et al., 2016

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity Rainer Kraehenmann, André Schmidt, Karl Friston, Katrin H. Preller, Erich Seifritz, Franz X. Vollenweider NeuroImage : Clinical, 2016, 11, 53–60 http://dx.doi.org/10.1016/j.nicl.2015.08.009   a b s t r a c t Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. We have recently shown that reduced amygdala activity during threat processing might underlie psilocybin's effect on emotional processing. However, it is still not known whether psilocybin modulates bottom-up or top-down connectivity within the visual-limbic-prefrontal network underlying threat processing.We therefore analyzed our previous fMRI data using [...]

Lire la suite

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer, Rafael Guimarães dos Santos et al., 2019

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer Rafael Guimarães dos Santos, José Carlos Bouso and Jaime E. C. Hallak BMC Psychiatry, 2019, 19, 321 https://doi.org/10.1186/s12888-019-2288-z   Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In [...]

Lire la suite

Modulation of Social Cognition via Hallucinogens and “Entactogens”, Katrin H. Preller and Franz X. Vollenweider, 2019

Modulation of Social Cognition via Hallucinogens and “Entactogens” Katrin H. Preller and Franz X. Vollenweider Frontiers in Psychiatry, décembre 2019 doi: 10.3389/fpsyt.2019.00881 Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning also represent a core aspect of many psychiatric disorders. Yet, despite its significance, deficits in social cognition skills are insufficiently targeted by current treatments. Hallucinogens and entactogens have been shown to have the potential to modulate social processing. This article reviews the literature on the influence of hallucinogens and entactogens on social processing in controlled experimental studies in humans and elucidates the underlying neurobiological and neuropharmacological mechanisms. Furthermore, [...]

Lire la suite

CBD & the Psychedelic Receptor, Lex Pelger, projectCBD.org, 2019

CBD & the Psychedelic Receptor Lex Pelger On March 11, 2018 (Updated on April 16, 2019) https://www.projectcbd.org/science/cbd-psychedelic-receptor CBD and LSD bind to the same serotonin receptor, which mediates psychedelic altered states. But cannabidiol has anti-psychotic properties and doesn't cause hallucinations. In a shorthand that drives scientists mad, serotonin is often called ‘the neurotransmitter of happiness.’ This tag is especially troublesome as more and more flaws become apparent in the ‘serotonin hypothesis’ of depression – the idea that depression is caused by a serotonin deficit, which a pill (a serotonin reuptake inhibitor) could correct.1  Serotonin is a complex molecule in the brain and the [...]

Lire la suite